Plain-English translation of NCT06358638 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Sickle Cell Disease research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing , a medication that blocks certain antibodies in the blood, given before a stem cell transplant from a healthy sibling. The goal is to help young patients with sickle cell disease who have developed antibodies against their donor's blood type — a situation that previously excluded them from this curative treatment.
Some patients with sickle cell disease develop antibodies against their sibling donor's blood type, which can cause dangerous complications after transplant and has prevented them from getting this life-changing treatment. Researchers are testing whether this medication can safely eliminate those antibodies and allow more patients with sickle cell disease to benefit from stem cell transplant.
You likely qualify if…
You likely don't qualify if…
You would receive four intravenous infusions of the medication over about three weeks. Then, after a 4-week break, you would undergo the conditioning phase — receiving a low-dose chemotherapy medication by injection and a small amount of radiation — followed by receiving your sibling's stem cells. You would stay in the hospital during the initial transplant phase and then be monitored closely for about one year as your new blood system engages and the medication given to prevent rejection is gradually reduced.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
United States